Newsroom

Strive to Deliver Breakthroughs

  1. February 07, 2023

    Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

    HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...

    View more
  2. January 26, 2023

    HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

    Cambridge, MA, January 26, 2023   HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142...

    View more
  3. January 19, 2023

    Harbour BioMed Announces IND Clearance for HBM1007 Targeting CD73 in the U.S.

    HBM1007 is a fully-human monoclonal antibody targeting CD73 HBM1007 is generated from Harbour Mice®  H2L2 platform With unique epitopes to...

    View more
  4. January 12, 2023

    Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA

    HBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...

    View more
  5. December 08, 2022

    Harbour BioMed Reports the Latest Progress from Phase I Clinical Trial of Porustobart in Combination with Toripalimab in Advanced Melanoma

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— December 8, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced the pro...

    View more
  6. December 02, 2022

    Invitation | Harbour BioMed Investor Day 2022

    View more
  7. November 25, 2022

    Harbour BioMed to Present the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody Porustobart with Unique Treg Depletion Mechanism at ESMO I-O 2022

     Cambridge, MA, Rotterdam, NL, Suzhou, CN— Nov 25, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced that ...

    View more
  8. November 21, 2022

    Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

    CAMBRIDGE, MA— November 21, 2022   Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution...

    View more
  9. November 14, 2022

    Harbour BioMed Launches Nona Biosciences’ “Ideas to IND” Preclinical Solutions Business to Accelerate Global Biotherapeutic Innovation

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2022   Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned sub...

    View more
  10. November 11, 2022

    Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 11, 2022   Harbour BioMed (the “Company”, HKEX: 02142) today announced that N...

    View more